Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stanford researchers test drug to fight depression faster in elderly

17.10.2002


Elderly people who suffer from depression can take the edge off faster by using a drug called mirtazapine, which appears to work more quickly compared to rival drugs. These results come from a study by researchers at Stanford University Medical Center who compared two drugs in an eight-week trial. Although both drugs treated the depression, mirtazapine began working sooner and eased the patient’s anxiety - a common effect of depression in elderly people.



"There’s a sense that we need something else for elderly patients and here is an alternative that is well tolerated," said Alan Schatzberg, MD, the Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences. "It gives doctors an alternative."

Anti-depression drugs come in two common varieties. Selective serotonin reuptake inhibitors (SSRIs), such as the popular Zoloft and Prozac, cause the brain chemical serotonin to linger in the gaps between neurons. These drugs are extremely effective but can interact with other drugs such as beta-blockers, which many elderly people take to quell heart problems.


The alternative to SSRIs - tricyclic antidepressants (TCAs) - can have side effects that make them less appealing. However, mirtazapine, a non-tricyclic that works similarly to TCA’s, has few side effects or drug interactions. "Mirtazapine has TCA-like properties without the side effects," Schatzberg said. "A lot of people use it where they might have used a TCA, particularly in the elderly." Mirtazapine enhances the effects of serotonin and other brain chemicals and also acts as a mild sedative.

Schatzberg tested mirtazapine’s effectiveness against paroxetine (sold under the name Paxil), a popular SSRI. In his trial, 255 depressed people 65 or older were randomly divided into groups taking either mirtazapine or paroxetine. Psychiatrists analyzed the patients’ depression throughout an eight-week test period.

Although the drugs were equally effective by the end of the eight-week period, depression in patients on mirtazapine had eased significantly by day 14 compared with people taking paroxetine. Those patients also had less anxiety and an easier time sleeping. In addition, those who took mirtazapine had fewer side effects such as nausea, tremors or flatulence - side effects that caused 26 percent of those taking paroxetine to discontinue the trial compared with 15 percent of those on mirtazapine. During an extended eight-week phase after the initial trial, the two drugs remained equally effective.

Schatzberg said mirtazapine is also effective more quickly than SSRIs in younger people; however younger people are less likely to stay on the drug because it can cause some weight gain and grogginess. "Weight gain is a problem for younger patients," Schatzberg said. "There’s less initiative to use the drug in these people."

These side effects that drive younger patients away can be a boon to the elderly who are less concerned about their weight but who suffer from anxiety and insomnia. "Depressed people who are older often have agitation," Schatzberg said. "Mirtazapine calmed these patients and helped them sleep, especially early on."

Schatzberg said that many doctors already use mirtazapine to treat depression in their elderly patients in order to avoid the drug interactions that are common with SSRIs. "But it certainly hasn’t saturated the market in the elderly," he noted.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

Im Focus: Computer-Designed Customized Regenerative Heart Valves

Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.

Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...

Im Focus: Light-induced superconductivity under high pressure

A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.

Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Supersonic waves may help electronics beat the heat

18.05.2018 | Power and Electrical Engineering

Keeping a Close Eye on Ice Loss

18.05.2018 | Information Technology

CrowdWater: An App for Flood Research

18.05.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>